Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1604 | GPs reports of potential patient safety incidents, non-COVID-19 related Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003141 | Communicable Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.05 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Professionals and residents of nursing homes are one of the most vulnerable groups in this public health crisis of COVID-19, since they have the highest rate of positives for COVID-19, despite the restriction measures carried out, such as prohibition of family visits to these centers, the infection occurs by cross transmission with the care staff of the centers, or with other residents. At the moment, there are no clinical trials to test the hypothesis that hydroxychloroquine is effective in coronavirus treatment. Although what has been observed is a better prognosis in infected patients, since this drug inhibits the replication of the virus and its expansion to other tissues. This study is a clinical trial to test the effectiveness of hydroxychloroquine as a preventive drug for SARS-CoV-2 infection. This drug will be applied to 1050 people residing in nursing home care and 880 professionals who work in close contact with these people and who have not yet contracted the infection. This project will be carried out in the territories of Madrid, Navarra, Aragon and Andalusia (Spain). Hydroxychloroquine is a widely known drug that is used in two scenarios, against autoimmune diseases, such as lupus or rheumatoid arthritis, and as an antimalarial drug. It is also intended to demonstrate that the presumed reduction in viral load that would be obtained with hydroxychloroquine prophylaxis, would have no effect in development of immunity against the virus. This fact can create a new paradigm for the de-escalation of the confinement to which the population has been subjected to stop the virus spread, allowing the development of general immunity in controlled populations until reaching total immunity. In addition to testing the effect of this drug, a non-pharmacological intervention based on a safety record will be tested in the management of infection on nursing home, to assess its effectiveness in detecting risk areas or bad practices carried out in this vulnerable environment. The study is led by researchers of the Institute of Biomedicine of Malaga (Spain), and has obtained a financing of 1,024,199 euros from Carlos III Health Institute (Spain). The period of execution of the clinical trial is one year, and with this intervention, the intention is to reduce cross-infection in residents by a minimum threshold of 15%, as well as to decrease infection in the professionals.
Description: Discrete quantitative variable. Residents with active viral load (diagnosed by polymerase chain reaction test) will be considered infected.
Measure: Number of secondary cases of SARS-CoV2 infection among residents at six days Time: This outcome will be evaluated at six days from the administration of chemoprophylaxis with hydroxychloroquineDescription: Discrete quantitative variable. Residents with active viral load (diagnosed by polymerase chain reaction test) will be considered infected.
Measure: Number of secondary cases of SARS-CoV2 infection among residents at 14 days Time: This outcome will be evaluated at 14 days from the administration of chemoprophylaxis with hydroxychloroquineDescription: Discrete quantitative variable. Residents with active viral load (diagnosed by polymerase chain reaction test) will be considered infected.
Measure: Number of secondary cases of SARS-CoV2 infection among residents at 28 days Time: This outcome will be evaluated at 28 days from the administration of chemoprophylaxis with hydroxychloroquineDescription: Dichotomous categorical variable
Measure: SARS-CoV-2 infection in nursing home staff who provide direct care at six days Time: This outcome will be evaluated at six days from the administration of chemoprophylaxis with hydroxychloroquineDescription: Dichotomous categorical variable
Measure: SARS-CoV-2 infection in nursing home staff who provide direct care at 14 days Time: This outcome will be evaluated at 14 days from the administration of chemoprophylaxis with hydroxychloroquineDescription: Dichotomous categorical variable
Measure: SARS-CoV-2 infection in nursing home staff who provide direct care at 28 days Time: This outcome will be evaluated at 28 days from the administration of chemoprophylaxis with hydroxychloroquineDescription: Dichotomous qualitative variable (1: Death 0: Survival)
Measure: Mortality Time: This outcome will be evaluated at 28 days from the administration of chemoprophylaxis with hydroxychloroquineDescription: Continous variable. It will be evaluated with the AIDS Clinical Trials Group method: investigation of medications not taken in a period of 4 days prior to the interview)% adherence = (total prescribed galenic units for that period-total units not taken) / total prescribed galenic units for that period
Measure: Compliance with treatment Time: It will be evaluated during the five days that the chemoprophylaxis with hydorxychloroquine is administeredDescription: Dichotomous categorical variable. The participant presents symptoms compatible with SARS-CoV-2 infection. High temperature, cephalea, dyspnea,diarrhea, vomiting, arthro-myalgia, pharynx pain, abdominal pain, anosmia, cough.
Measure: Symptoms of SARS-CoV-2 infection at six days Time: This outcome will be evaluated at 6 days from the administration of chemoprophylaxis with hydroxychloroquineDescription: Dichotomous categorical variable. The participant presents symptoms compatible with SARS-CoV-2 infection. High temperature, cephalea, dyspnea,diarrhea, vomiting, arthro-myalgia, pharynx pain, abdominal pain, anosmia, cough.
Measure: Symptoms of SARS-CoV-2 infection at 14 days Time: This outcome will be evaluated at 14 days from the administration of chemoprophylaxis with hydroxychloroquineDescription: Dichotomous categorical variable. The participant presents symptoms compatible with SARS-CoV-2 infection. High temperature, cephalea, dyspnea,diarrhea, vomiting, arthro-myalgia, pharynx pain, abdominal pain, anosmia, cough.
Measure: Symptoms of SARS-CoV-2 infection at 28 days Time: This outcome will be evaluated at 28 days from the administration of chemoprophylaxis with hydroxychloroquineDescription: Dichotomous categorical variable. Participant requires hospital admission attributable to SARS-CoV-2 infection
Measure: Hospitalization Time: This outcome will be evaluated at 28 days from the administration of chemoprophylaxis with hydroxychloroquineDescription: Polycotomic categorical variable. Collected by clinical interview and also monitored simultaneously by external trial monitors
Measure: Adverse events at six days Time: This outcome will be evaluated at six days from the administration of chemoprophylaxis with hydroxychloroquineDescription: Polycotomic categorical variable. Collected by clinical interview and also monitored simultaneously by external trial monitors
Measure: Adverse events at 14 days Time: This outcome will be evaluated at 14 days from the administration of chemoprophylaxis with hydroxychloroquineDescription: Polycotomic categorical variable. Collected by clinical interview and also monitored simultaneously by external trial monitors
Measure: Adverse events at 28 days Time: This outcome will be evaluated at 28 days from the administration of chemoprophylaxis with hydroxychloroquineAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports